Checkpoint Inhibitors and the Gut

Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Tuan, Tran, Nguyen Giang Tien, Ho, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836963/
https://www.ncbi.nlm.nih.gov/pubmed/35160275
http://dx.doi.org/10.3390/jcm11030824
_version_ 1784649806889615360
author Tran, Tuan
Tran, Nguyen Giang Tien
Ho, Vincent
author_facet Tran, Tuan
Tran, Nguyen Giang Tien
Ho, Vincent
author_sort Tran, Tuan
collection PubMed
description Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.
format Online
Article
Text
id pubmed-8836963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88369632022-02-12 Checkpoint Inhibitors and the Gut Tran, Tuan Tran, Nguyen Giang Tien Ho, Vincent J Clin Med Review Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction. MDPI 2022-02-04 /pmc/articles/PMC8836963/ /pubmed/35160275 http://dx.doi.org/10.3390/jcm11030824 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tran, Tuan
Tran, Nguyen Giang Tien
Ho, Vincent
Checkpoint Inhibitors and the Gut
title Checkpoint Inhibitors and the Gut
title_full Checkpoint Inhibitors and the Gut
title_fullStr Checkpoint Inhibitors and the Gut
title_full_unstemmed Checkpoint Inhibitors and the Gut
title_short Checkpoint Inhibitors and the Gut
title_sort checkpoint inhibitors and the gut
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836963/
https://www.ncbi.nlm.nih.gov/pubmed/35160275
http://dx.doi.org/10.3390/jcm11030824
work_keys_str_mv AT trantuan checkpointinhibitorsandthegut
AT trannguyengiangtien checkpointinhibitorsandthegut
AT hovincent checkpointinhibitorsandthegut

Ejemplares similares